blog.aids.gov − Carl Dieffenbach, Ph.D.
AIDS.GOV | SERVICE LOCATOR | SEARCH

BLOG.AIDS.GOV - Changing to HIV.gov in Spring 2017

MENU

Carl Dieffenbach, Ph.D.

Director of the Division of AIDS, NIAID 

Prevention Studies In 2016 Set the Stage for Progress

It is fitting that in the year that we marked the 35th anniversary of the first recognition of what would come to be known as HIV, we’ve taken major steps toward revolutionizing how we could prevent this disease. In 2016 we began four important clinical studies that promise to inform HIV prevention research, which may…

NIH Statement on World AIDS Day 2015: Follow the Science to Fast-Track the End of AIDS

When the first cases of what would become known as AIDS were reported in 1981, scientists and physicians did not know the cause and had no therapies to treat those who were infected. Times have changed and today physicians can offer their patients highly effective medicines that work as both treatment and prevention. We can…

NIH’s Dr. Carl Dieffenbach Shares Highlights as CROI 2015 Begins (Video)

As the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) got underway in Seattle yesterday, February 23, we spoke with Dr. Carl Dieffenbach, Director of the Division of AIDS at NIH’s National Institute of Allergy and Infectious Diseases (NIAID). He discussed what we can anticipate hearing more about during this annual scientific meeting that brings…

Prevention and Treatment of HIV Infection in Infants Born to Infected Mothers: Need for a Fresh Look

On Monday, March 4, 2013, at the Conference on Retroviruses and Opportunistic Infections (CROI) in Atlanta, Dr. Deborah Persaud of the Johns Hopkins University presented an intriguing case study of a child who by all measures seems to be cured of HIV infection. This single case has sparked significant conversation, debate, and optimism. This blog…

Community Engagement in NIAID’s HIV/AIDS Clinical Trials Networks

Since early in the HIV/AIDS epidemic, the National Institute of Allergy and Infectious Diseases (NIAID) has involved community representatives and advocates in the research process.   The nature and scope of the community’s involvement have grown over the years, but the rationale behind these efforts remains the same:  the people who might benefit from the research…

New Announcement about PrEP from NIH

The National Institutes of Health National Institute of Allergy and Infectious Diseases just made a significant announcement on pre-exposure prophylaxis (PrEP). I am proud to share this important update from the NIH with our blog readers. Learn more by reading this Q&A.

What’s in it for Non-AIDS Infectious Diseases Researchers?

Co-authored by Hugh Auchincloss, M.D., NIAID Deputy Director and Carole Heilman, Ph.D., Director of NIAID’s Division of Microbiology and Infectious Diseases So far all of the postings on this blog series have been about HIV/AIDS research or about diseases that are major comorbidities. This is appropriate since we have been discussing the upcoming re-competition of…

Advancing Pediatric, Maternal and Child Health

Co-authored by Edward Handelsman, M.D., Chief of NIAID’s Pediatric Medicine Branch within the Division of AIDS, and Lynne Mofenson, M.D., Chief of the Pediatric, Adolescent and Maternal AIDS Branch within the Eunice Kennedy Shriver National Institute of Child Health & Human Development. As a result of our continued dialogue with our collaborators and stakeholders, NIAID…